

Comparison of Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients

Laksmi Wulandari, Gatot Soegiarto, Anna Febriani, Farah Fatmawati & Sahrin

Indian Journal of Surgical Oncology

ISSN 0975-7651

Indian J Surg Oncol

DOI 10.1007/s13193-020-01046-1



Your article is protected by copyright and all rights are held exclusively by Indian Association of Surgical Oncology. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".



Indian Journal of Surgical Oncology

[Journal home](#) > Editors

Editors

Chairman/ Editor

Prof.K.S.Gopinath,

Director HCG, Bangalore Institute of Oncology

44/45, 2nd Cross, Raja Ram Mohan Roy Extension,

Off K.H. Double Road.

Bangalore – 560027, Karnataka, India.

President IASO

Dr. Arnab Gupta

Medical Director,

Prof. Department of Surgical Oncology,

Saroj Gupta Cancer Centre & Research Institute,

Thakurpukur, Kolkata

Immediate past president

Dr. Dhairyasheel Sawant

Consultant Surgical Oncologist,

Asian Institute of Oncology,

Off Easter Express Highway, Behind Everard Nagar

Somaiya Ayurvihar, Sion(East), Mumbai, Maharashtra 400022

President Elect IASO

Dr. Rajendra Toprani,

Senior Consultant, Head & Neck Surgical Oncologist,

Director, Aastha Oncology Associates,

For authors

[Submission guidelines](#)

[Ethics & disclosures](#)

[Open Access fees and funding](#)

[Contact the journal](#)

Submit manuscript

Explore

[Online first articles](#)

[Volumes and issues](#)

Sign up for alerts

Director, HCG Cancer Center,

Ahmedabad.

Vice president

Dr. Prafulla K.Das

Prof of Surgical Oncology,

Regional Cancer Institute, Cuttack, Odisha, INDIA.

Secretary IASO

Dr.Sharadh Desai

Mahatma Gandhi Cancer Hospital,

Miraj - 416410.

Treasurer:

Dr. K.Chandra Mohan

Additional Professor

Department of Surgical Oncology

Regional Cancer Centre

Trivandrum 695011

Kerala India

IASO past Secretary

Dr.RajendraToprani,

Senior Consultant, Head & Neck Surgical Oncologist,

Director, Aastha Oncology Associates,

Director, HCG Cancer Center,

Ahmedabad.

Editorial secretary

Dr. Asuthosah Chauhan

Consultant Surgical Oncologist,

HCG –SMH, Cancer Institute , New Delhi

IASO EXECUTIVE members 2019 – 2020

South Zone

Dr.Ramakrishnan

Dr.Sandeep Nayak

East Zone

Dr.Celeb harris

Dr. Shaikat Gupta

West Zone

Dr. Atul Samaiya

Dr. Sanjay Desai

North Zone

Dr.Naveen Sancheti

Dr.Sandeep Agarwal

IJSO Website in charge

Dr.Shubam Jain,

Max Hospital, Saket, New Delhi

IJSO Executive Editorial council**IJSO Associate editors****Prof.K.Harish,**

Prof. of Surgical Oncology

M.S.R Medical College,

Bangalore, India

IJSO joint editors**Prof. Arvind Krishnamurthy**

Prof. of Surgery

Adyar Cancer Institute, Chennai

Dr.Narendra Hulikal

Prof & head Surgical Oncology

SVIMS , Tirupathi

Assistant to Associate Editor

Dr.Arvind S Kapali

Assistant Prof. Dept.of Surical Oncology,

M.S.R.Medical College, Bengaluru

SECTIONAL EDITORS**Gynaecological Oncology****Dr.D.K..Vijay Kumar**

Prof. of Surgical Oncology,

Amritha Institute of Medical Science

Amrita Institute of Medical Science,

Kochi

Head & neck

Dr. Somesh Chandara –

Consultant, Surgical oncologist

Sterling hospital, Ahmedabad

Thoracic

Dr.Rajesh Mistry

Thoracic Oncologist

Kokilaben hospital

Mumbai

GI Oncology

Dr.Suraj Manjunath –

Surgical Oncologist

Vikaram Hospital , Bangalore

GI Oncology

Dr.Avinash Saklani –

Prof. of Surgical Oncologist,

Tata memorial Hospital,

Mumbai

Peritoneal Surface

Dr. Aditi Bhatt

Surgical Oncologist,

Zydus Hospital,

Ahmadabad

Breast

Dr. Vani Paramar –

Professor, Surgical Oncology,

Research and Education in Cancer (ACTREC),

Tata Memorial Centre

Kharghar, Navi Mumbai

Kharighat, Navi Mumbai,

Maharashtra 410210

Bone & Soft tissues

Dr.Anand Raja

Prof.Surgical Oncology

Adiyar cancer Institute

Chennai

NATIONAL ADVISORY COMMITTEE

Dr. D.D.Patel

Shaleen Complex,
Near Gh 5 circle, Sector 22,
17/22 Bus stop, Gandhi Nagar,
Ahamedabad,
Gujarath - 382010

Dr.Sanjay Sharma

Director, & prof surgical oncology,
Asian cancer institute,

Off Easter Express Highway, Behind Everard Nagar

Somaiya Ayurvihar, Sion(East), Mumbai, Maharashtra 400022

Dr.Anil D Cruz,

Director Tata Memorial Hospital

Professor & Surgeon

Chief Head Neck Services

Tata Memorial Hospital

Parel Mumbai 400012

Dr.S.P.Somashekar,

Manipal Hospital,

Bangalore

Dr.Sanjeev Misra,

Director,

AIIMS, Jodhpur , Rajasthan

Dr.G.K.Rath

Director, IRCH & NCI New Delhi

INTERNATIONAL ADVISORY COMMITTEE

Dr.Graham Poston

Royal Liverpool University Hospital,

Department of Surgery,
Greenbank Road, Liverpool, England,
Liverpool, UK.
L18 1HQ Tel: Work 0151 733 7123

Dr. AshokShaha

Chairman – Head and Neck Services

Memorial Sloan-Kettering Cancer Center

1275 York Avenue
New York, NY 10065

Dr. Hang Wang Yang

Department of Surgery, Seoul National University

College of Medicine

101 Daehak-no, Jongno-gu, Seoul 03080 KOREA

Prof.Kazuhiro Yoshida M.D., Ph.D.

Professor, Department of Surgical Oncology

Graduate School of Medicine, Gifu University, Japan.

Prof. Nam Kyu Kim

Department of Surgery,

Yonsei University College of Medicine,

50 Yonsei-ro Seodaemun-gu,

Seoul 03722, Korea

Dr.Ashuthosh Kotari,

Guys Hospital, UK

Prof.Ismail Jatoi,USA

Dale H. Dorn Chair in Surgery

Professor and Chief, Division of Surgical Oncology and Endocrine Surgery

University of Texas Health Science Center

7703 Floyd Curl Drive, Mail Code 7738

San Antonio, Texas 78229

USA

Dr. Sai Yendamuri , USA

Associate Professor,

Department of Thoracic Oncology,

Director, Thoracic Surgery Research Laboratory, Roswell Park Cancer Institute.

Dr. Chandra Are,

Jerald L & Carolynn J Varner Professor Surgical Oncology & Global Health

Associate Dean Graduate Medical Education (DIO)

Vice Chair Education Department of Surgery

University of Nebraska Medical Center

Omaha, NE. 68198

Dr. Christopher Booth

Professor of Medical Oncology

Canada Research Chair in Population Cancer Care

Queen's University

Kingston, Canada

Dr. David Rew

Consultant Surgeon,

University Hospital of Southampton UK

Dr. Donald Weaver

Dept of Surgery

3990 John R

Detroit, Michigan 48201

USA

IJSO EDITORIAL BOARD

Dr. M.Vijay Kumar

Vice Chancellor, Yenepoya University,

Mangalore

Vice President, OSTOMATES INDIA

Past President, Indian Association of Surgical Oncology (2015) ,

Former Director,

Kidwai Memorial Institute of Oncology,

Bangalore

Dr. Ravikanth ,

Director, AIIMS, Rishikesh

Dr. Arunchaturvedi

Prof. of Surgical Oncology
King George medical Hospital,

Lucknow (India)

Dr. Subramanneshwar Rao

Medical Director & Chief Surgical Oncologist

Basavatarakam Indo American Cancer Hospital & Research Centre

Road no.14, Banjara Hills

Hyderabad .500034

Telangana, INDIA

Dr. Satheesan.P

Professor, Director
Surgical Oncology
Malabar Cancer Centre, South Bazaar, Kerala 670002
India

Dr. Raman Deshpande,

Chairman ICC 2021

Asian Cancer Institute,

Mumbai. India.

 Springer

Publish with us

Authors & Editors

Journal authors

Publishing ethics

Open Access & Springer

Discover content

SpringerLink

Books A-Z

Journals A-Z

Video

Other services

Instructors

[Instructions](#)

[Librarians \(Springer Nature\)](#)

[Societies and Publishing Partners](#)

[Advertisers](#)

[Shop on Springer.com](#)

About Springer

[About us](#)

[Help & Support](#)

[Contact us](#)

[Press releases](#)

[Impressum](#)

Legal

[General term & conditions](#)

[California Privacy Statement](#)

[Rights & permissions](#)

[Privacy](#)

[How we use cookies](#)

[Manage cookies/Do not sell my data](#)

[Accessibility](#)

Not logged in - 103.109.155.124

Not affiliated

SPRINGER NATURE

© 2022 Springer Nature Switzerland AG. Part of [Springer Nature](#).



Indian Journal of Surgical Oncology

[Journal home](#) > [Volumes and issues](#) > [Volume 12, supplement issue 1](#)

Search within journal

Volume 12, supplement issue 1, April 2021

Supplement 1 on Molecular Oncology

31 articles in this issue

V Shanta - Tribute to the Legend and a Saint

K. Harish & K. S. Gopinath

Obituary | Published: 06 March 2021

Pages: 1 - 6



Molecular Biology in the Breast Clinics—Current status and future perspectives

Vani Parmar, Nita S Nair ... Garvit Chitkara


Review Article | Published: 10 August 2019 | Pages: 7 - 20

CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario

Satish Sankaran, Jyoti Bajpai Dikshit ... Manjiri M. Bakre

Original Article | [Open Access](#)

Published: 09 December 2019 | Pages: 21 - 29



Genetic Counseling Clinic at AIIMS (New Delhi)


Dhritiman Maitra, Payal Manek ... Anurag Srivastava

Original Article | Published: 04 April 2020 | Pages: 30 - 33

Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies

Sanjoy Das, Bireswar Bhattacharya ... Kishan Paul

Original Article | Published: 19 August 2019



For authors

[Submission guidelines](#)

[Ethics & disclosures](#)

[Open Access fees and funding](#)

[Contact the journal](#)

Explore

[Online first articles](#)


[Volumes and issues](#)

TRF2 Overexpression at the Surgical Resection Margin: A Potential Predictive Biomarker in Oral Squamous Cell Carcinoma for Recurrence

Madhabananda Kar, Mahesh Sultania ... Birendranath Banerjee

Original Article

Published: 19 February 2020 | Pages: 46 - 51




microRNAs: New-Age Panacea in Cancer Therapeutics

Neelanjana Sarkar & Arun Kumar

Review Article | Published: 06 June 2020

Pages: 52 - 56




Molecular Oncology of Gall Bladder Cancer

Arun Chaturvedi, Vijay Kumar & Sameer Gupta

Review Article

Published: 16 November 2019 | Pages: 57 - 64



Comparison of Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients

Laksmi Wulandari, Gatot Soegiarto ... Sahrnun

Original Article

Published: 05 February 2020 | Pages: 65 - 71

Testing at Dr. Soetomo General Hospital, Surabaya, Indonesia, from January-December 2018


- 8 patients were excluded:
 - 5 patients had non-representative sample slides of histopathologic results.
 - 3 patients had metastasis of lung adenocarcinoma from other locations
 - 1 patient died before ctDNA sampling, therefore only cytological sample was available

GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma

Meenatai Naik, B. Vishal Rao ... Sundaram Challa

Original Article

Published: 18 January 2020 | Pages: 72 - 78




Role of CAIX Expression in Conventional Renal Cell Carcinomas as a Diagnostic Marker and its Prognostic Importance

Kavitha Ramachandran, Bindhu M.R ... Appu Thomas


Original Article

Published: 20 July 2020

Pages: 79 - 84



mRNA Expression Analysis of E-Cadherin, VEGF, and MMPs in




Gastric Cancer: a Pilot Study

Puneet Kumar, Arun Sebastian ... Gopeshwar Narayan

Original Article | Published: 22 May 2020 |

Pages: 85 - 92




Neuropeptide Substance P Enhances Inflammation-Mediated Tumor Signaling Pathways and Migration and Proliferation of Head and Neck Cancers

Sumeet Singh, Subhashree Kumaravel ... Sanjukta Chakraborty

Original Article |

Published: 01 September 2020 |

Pages: 93 - 102



Molecular Signatures of Gynecological Cancers: Clinicians Perspective

TS Shylasree, Bansal Richa ... Seema Gulia


Review Article | Published: 02 February 2021 | Pages: 103 - 110

Analysis of SET and MYND Domain-Containing Protein 3 (SMYD3) Expression in Gallbladder Cancer: a Pilot Study

Pushkar Chandra, Ruhi Dixit ... Vijay Kumar Shukla

Original Article | Published: 11 July 2020 |

Pages: 111 - 117



Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine

Samarth Hegde


Review Article | Published: 25 August 2020 | Pages: 118 - 127

β -Catenin—a Possible Prognostic Molecular Marker for Recurrence in Histopathologically Negative Surgical Margin of Oral Cancer

Madhabananda Kar, Mahesh Sultania ... Birendranath Banerjee

Original Article |


Published: 11 October 2020 | Pages: 128 - 133



Negative Prognostic Implication of *TERT* Promoter Mutations in Human Papillomavirus–Negative Tonsillar Squamous Cell Carcinoma Under the New 8th AJCC Staging System

Hyunchul Kim, Mi Jung Kwon ... Hyo Jung Kim

Original Article |




Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma

Animesh Saurabh, Vandana Raphael ... Umesh Das

Original Article |

Published: 16 October 2020 | Pages: 144 - 151




Prevalence of Molecular Subtypes of Breast Cancer in India: a Systematic Review and Meta-analysis

Pavan Kumar Jonnada, Cherukuru Sushma ... Anvesh Dharanikota

Review Article | Published: 28 October 2020 |

Pages: 152 - 163



Clinical and Histopathological Correlation of p16 and p53 Expression in Oral Cancer

Varun Kumar Agarwal, Rohit Sharma ... Amiy Arnav


Original Article | Published: 24 August 2020 | Pages: 164 - 168

Molecular Oncology in Management of Colorectal Cancer

Ramraj Nagendra Gupta Vemala, Sanjeev Vasudev Katti ... Govind Nandakumar

Original Article | Published: 16 March 2021 |

Pages: 169 - 180




Bilateral Primary Ovarian Clear Cell Carcinoma in an Iranian Woman: a Case Report

Fatemeh Samiee-Rad, Mahdi Ghaebi & Arezoo Bajelan

Case Report | Published: 01 October 2020 |

Pages: 181 - 185




Functional Malignant Retroperitoneal Paraganglioma with Liver Metastasis: a Rare Case Report

Sachin S. Kadam, Sujai Hegde ... Tejaswini Kadam

Case Report | Published: 05 January 2021 |


Pages: 186 - 192



Solitary Pancreatic Head Metastasis from Ductal Carcinoma of Breast: A Case Report

Parag Ingle, Pravin Khandare ... Ajay Mehta

Case Report | Published: 03 February 2021 |




Dural Metastasis from Breast Carcinoma Mimicking Sub-acute Subdural Hematoma: a Case Report

Alejandro Augusto Ortega Rodriguez, Macarena Centeno Haro ... Jordi de Manuel-Rimbau Muñoz

Case Report | Published: 01 February 2021 |

Pages: 197 - 200




A Rare Case of Epithelioid Myofibroblastoma of Breast Mimicking Lobular Carcinoma on Trucut Biopsy: a Diagnostic Pitfall and Literature Review

Amrita Talwar, Swasti Jain ... Purnima Paliwal

Case Report | Published: 02 March 2021 |

Pages: 201 - 204




Liposarcoma of the Parapharyngeal Space: a Rare Entity

Pankaj Kumar Sahu, Jitendra Bothra ... Hari Mukundan

Case Report | Published: 27 February 2021 |

Pages: 205 - 209




Adaptations and Safety Modifications to Perform Safe Minimal Access Surgery (MIS: Laparoscopy and Robotic) During the COVID-19 Pandemic: Practice Modifications Expert Panel Consensus Guidelines from Academia of Minimal Access Surgical Oncology (AMASO)

S. P. Somashekhar, Rudra Acharya ... Arnab Gupta

Review Article |

Published: 18 November 2020 |

Pages: 210 - 220




Lymphangioma of Pancreas Masquerading as a Pancreatic Cystic Neoplasm


Munita Bal, Komal Kathuria ... Shailesh V. Shrikhande

Case Report | Published: 12 March 2021 |

Pages: 221 - 223



Sebaceous Cell Carcinoma of the Lower Eyelid in an Elderly Male: a Rare Case Report and Review of Literature



Literature

Sachin S. Kadam, Tejaswini Kadam ... Sanjay M . H.

Case Report | Published: 23 March 2021 |

Pages: 224 - 227

Not logged in - 103.109.155.124

Not affiliated

SPRINGER NATURE

© 2022 Springer Nature Switzerland AG. Part of [Springer Nature](#).



Comparison of Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients

Laksmi Wulandari¹ · Gatot Soegiarto² · Anna Febriani¹ · Farah Fatmawati¹ · Sahrun³

Received: 30 April 2019 / Accepted: 27 January 2020

© Indian Association of Surgical Oncology 2020

Abstract

The ctDNA plasma testing is one of the methods to examine biomarkers for lung adenocarcinoma in order to detect a mutation of epidermal growth factor receptor (EGFR) gene. The advantages of ctDNA testing over tissue biopsy and lung tumor cytology include less invasive, faster result, cheaper, and minimum risk of complication for the patient. We analyzed and compare the detection of EGFR mutation in peripheral blood plasma (liquid biopsy) with cytological specimens of patients with lung adenocarcinoma. We conducted ctDNA plasma testing in 124 lung adenocarcinoma patients who visited our hospital from January to December 2018. The ctDNA testing results were compared with the results of EGFR detection from the previous cytological specimen examination. Most of the patients were males, aged 55–59 years, nonsmokers, and had stage IVA lung adenocarcinoma, with most metastasis found in the pleura. We found a correlation between EGFR prevalence with nonsmoking status and patient's age. The ctDNA plasma testing detected 27.4% common EGFR mutation and 72.6% wild-type EGFR. The figures of EGFR mutation detection from cytological specimens were 47.6% and 52.4%, respectively. Compared to cytological specimens, the EGFR mutation detection in ctDNA had a sensitivity of 48.3%, with a specificity of 90.9%, PPV of 82.35%, NPV of 66.7%, and 70.97% concordance rate. EGFR mutation with cytological specimen examination was more accurate than ctDNA.

Keywords Concordance rate · ctDNA plasma · EGFR mutation · Lung adenocarcinoma

✉ Laksmi Wulandari
laksmi.wulandari@fk.unair.ac.id

Gatot Soegiarto
gatot_soegiarto@fk.unair.ac.id

Anna Febriani
febrianianna@gmail.com

Farah Fatmawati
farahummufeno@yahoo.co.id

Sahrun
cahrun.carter@gmail.com

¹ Thoracic Oncology Division, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Jl. Mayjen Prof. Dr. Moestopo no. 6-8, Surabaya 60286, Indonesia

² Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia

³ Thoracic Oncology Division, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia

Introduction

Lung cancer is one of the leading causes of cancer death in the world. There are two main types of lung cancer, non-small cell lung cancer (NSCLC) consisted of 80% and small cell lung cancer (SCLC) consisted of 20% of all lung cancer. The NSCLC consisted mostly of adenocarcinoma, followed by squamous cell carcinoma, and large-cell carcinoma. Lung adenocarcinoma is the most common NSCLC type found in the world [1–3].

Lung cancer is the top 3 most common cancer found in Indonesia along with breast cancer and cervical cancer. Lung cancer is a cancer with the highest prevalence in men. Based on data from Dharmais National Cancer Hospital, Jakarta, Indonesia, the prevalence of lung cancer had been increasing from 2010 to 2013, where 117 cases took place in 2010 with 38 deaths, 163 cases in 2011 with 39 deaths, 165 cases in 2012 with 62 deaths, and 173 cases in 2013 with 65 deaths [4].

The incident of lung adenocarcinoma has been increasing as well in Asia and in the USA, particularly in women, young adults, and nonsmokers. The US data showed that lung adenocarcinoma was found in 31–54% of nonsmoker men, higher than

in smoker men (25%–33%), and 49–74% of nonsmoker women, which also higher than in smoker women (33%–43%) [5].

Epidermal growth factor receptor (EGFR) mutation in NSCLC is particularly found in lung adenocarcinoma. It has an important role in the last 10 years as a target of cancer therapy. Advanced NSCLC patients with EGFR activating mutation, i.e., exon 18, exon 19, and exon 21, showed much better response when given EGFR tyrosine kinase inhibitor (TKI) as the treatment compared to standard chemotherapy [6, 7]. This advantage can only be achieved if the adequate materials or samples and tools are available. However, the success of EGFR mutation testing is often hindered by tissue availability, so that the patients often lose the opportunity to get the targeted therapy due to the insufficient tissue for histological or cytological examination.

Current mutation testing can alternatively be conducted with liquid biopsy using EGFR mutation detection from blood plasma. A study of EGFR mutation prevalence taken from tissue and blood conducted by Implementing GeNomics In pracTicE (IGNITE study) was done in Asia-Pacific and Russia and found that EGFR mutation in lung adenocarcinoma tissue was higher in Asia-Pacific than in Russia (49.3% vs. 18%). The study also found a concordance of EGFR mutation testing results between tissue and blood samples of 2581 patients (80.5% concordance rate, 46.5% sensitivity, and 95.6% specificity) [8]. The result is quite convincing, with 95.6% specificity, so that EGFR mutation testing from blood samples can be used as a screening method for NSCLC cases. Studies on this topic have not been conducted widely in Indonesia, particularly in Surabaya. Therefore, we conducted this research to determine the prevalence of EGFR mutation in NSCLC patients of adenocarcinoma histopathology at Dr. Soetomo General Hospital, Surabaya, Indonesia, and to compare the results of EGFR mutation detection in blood plasma samples to the results of cytological samples examination.

Methods

This study was an analytical observational research conducted in 124 consecutive lung adenocarcinoma patients who visited Dr. Soetomo General Hospital, Surabaya, Indonesia, from January to December 2018 (Fig. 1). The inclusion criteria were lung adenocarcinoma patients who had been previously diagnosed with cytological samples, had not received any cancer treatment, and had cytological sample slides with sufficient cell numbers that can be analyzed (minimum of 50 cells). Patients who had adenocarcinoma lesions in the lungs as metastases from other organs and having nonrepresentative cytological samples were excluded from this study. All eligible subjects were giving their consent. This study was approved by the Ethic Committee of Dr. Soetomo General Hospital, Surabaya (certificate No. 0209/KEPK/IV/2018).

There were 132 lung cancer patients underwent ctDNA plasma testing at Dr. Soetomo General Hospital, Surabaya, Indonesia, from January-December 2018

8 patients were excluded:

- 5 patients had non-representative sample slides of histopathologic results,
- 3 patients had metastasis of lung adenocarcinoma from other locations
- 1 patient died before ctDNA sampling, therefore only cytologic sample was available

A total of 124 patients met the inclusion criteria

Fig. 1 Flow diagram of subject recruitment

The examination of EGFR mutations status from cytological samples was done in the Pathology Anatomy Laboratory of Dr. Soetomo Hospital. The EGFR examination of cytological samples used the DNA extraction method (GeneAll Exgene™ Cell SV), real-time quantitative PCR (high-resolution melting analysis) analyzed with LightCycler 480 II real-time PCR (Roche, Basel, Switzerland), and AmoyDx® EGFR Adx-ARMS® (Amoy Diagnostics, Xiamen, China).

The EGFR mutation detection from patient's blood plasma specimens was done in Prodia Laboratory, Surabaya, Indonesia. Approximately 10-mL blood sample was withdrawn from each patient, which was then centrifuged into blood plasma, stored in a special frozen container, and transferred to the laboratory. The blood plasma was then analyzed for EGFR mutation using real-time PCR Scorpion-ARMS with theascreen® EGFR plasma RGQ PCR kit (QIAGEN, Manchester, UK). The target detections of this examination were exon 19 deletions, T790 M mutation in exon 20, and L858R point mutation. The detection limit was in accordance with the provisions of the corporation. The work steps for DNA extraction and for EGFR mutation detection were done according to the manufacturer's instruction. This method had been reported previously elsewhere [9]. The results of ctDNA were then compared with the results of EGFR mutation testing from cytological samples.

A diagnostic test was conducted to determine the correlation between EGFR ctDNA results and cytological specimens, in terms of sensitivity and specificity. The concordance rate test was performed to examine the conformity between ctDNA and cytological specimens. Cross-tabulation and logistic regression tests were done to examine the relationship between disease stage, sex, age, and smoking status with the results of EGFR mutations on ctDNA with 95% confidence intervals (CI) and p value < 0.05 . Statistical analysis was conducted using IBM SPSS Statistics software version 23.0 (IBM Corp., Armonk, NY, USA).

Results

Subject Characteristics

Most of the subjects were males (58.1%), in the age group of 55–59 years (22.6%). The majority of the study subjects were nonsmokers (51.6%), while 21.0% of them were active

Table 1 Subject characteristics

Characteristics	n (%)
Age	
30–34 years	2 (1.6%)
35–39 years	6 (4.8%)
40–44 years	5 (4.0%)
45–49 years	6 (4.8%)
50–54 years	25 (20.2%)
55–59 years	28 (22.6%)
60–64 years	22 (17.7%)
65–69 years	10 (8.1%)
70–74 years	13 (10.5%)
75–79 years	6 (4.8%)
80–84 years	1 (0.8%)
Sex	
Male	72 (58.1%)
Female	52 (41.9%)
Smoking status	
Active Smoker	26 (21.0%)
Nonsmoker	64 (51.6%)
Ex-smoker	34 (27.4%)
Tissue origin	
Open biopsy	5 (4.0%)
Core biopsy	18 (14.5%)
Bronchoalveolar lavage (BAL)	7 (5.6%)
Bronchial brushing	2 (1.6%)
FNAB lung	74 (59.7%)
FNAB cervical lymph node	4 (3.2%)
Pleural fluid cytology	14 (11.3%)
Diagnosis	
Lung adenocarcinoma (right lung)	87 (70.2%)
Lung adenocarcinoma (left lung)	37 (29.8%)
Stage	
IIA	2 (1.6%)
IIIB	3 (2.4%)
IIIA	11 (8.9%)
IIIB	5 (4.0%)
IIIC	6 (4.8%)
IVA	83 (66.9%)
IVB	14 (11.3%)

FNAB fine-needle aspiration biopsy

smokers (Table 1). Most of smoking subjects were in the age group of 40–49 (15.3%), and the highest number of cigarettes smoked was around 10–19 per day (24.2%).

Most of the study subjects had adenocarcinoma of the right lung (70.2%). The majority of cytological specimens' examination for the diagnosis of lung adenocarcinoma was taken from lung fine-needle aspiration biopsy (FNAB) which was 59.7%. Most of the patients (66.9%) had stages IVA disease (Table 1). Tumor metastases were found to be diverse; most metastases were in the pleura (52.4%), followed by bone metastases (including vertebral bones, ribs, and other large bones) in 9.7% of the patients. The EGFR mutation was detected in 47.6% of patients from cytological specimens and in 27.4% of patients from ctDNA. The type of EGFR mutation was dominated by the common mutations, i.e., in exon 19 (30.6% in cytological specimens and 19.4% in ctDNA) and exon 21 L858R (14.5% in cytological specimens and 7.3% in ctDNA). The results of EGFR mutation detection by the two methods can be seen in Fig. 2.

Association of Age, Sex, Smoking Status, and Disease Stage on EGFR Mutation Results


The age and the smoking behavior of the study subjects were significantly correlated with EGFR mutations detected in ctDNA ($\beta = 0.220$; $p = 0.042$ and $\beta = 1.740$; $p < 0.001$, respectively). There was no significant correlation between sex and the EGFR mutation ($\beta = -0.030$; $p = 0.961$) as can be seen in Table 2.

The ctDNA detection of EGFR mutation is more likely positive in more advanced stage lung cancer. In other words, subjects with advanced disease stages had the highest probability of EGFR mutations detected in ctDNA. Most of our subjects were in stage IVA lung adenocarcinoma. Positive EGFR mutations were detected in 30.12% (25/83) of stage IVA patients but only in 16.6% (1/6) of stage IIIC patients. No ctDNA detection of EGFR mutations was found in patients with stage IIA to IIIB diseases (Table 3).

Concordance of ctDNA EGFR Mutation Results and Cytological Specimens

Analysis of concordance of EGFR mutation detection results between liquid biopsy (ctDNA) and cytological specimens was done to obtain the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and concordance rate. Compared to detection in cytological specimens, the EGFR mutation detection in ctDNA had a sensitivity of 48.3%, with a specificity of 90.9%, PPV of 82.35%, NPV of 66.7%, and 70.97% concordance rate (Table 4).

Fig. 2 EGFR mutation detection in cytologic samples and ctDNA



Discussion

Our study showed a good correlation and concordance between EGFR mutation status detected in plasma samples (liquid biopsy) and cytological specimens. Our finding was also in accord with the results of the IGNITE study which also included patients from our hospital [8]. This is of particular interest, because now we can use ctDNA or plasma biopsy to detect EGFR mutations in adenocarcinoma NSCLC patients in whom an adequate tissue sample cannot be obtained.

Most subjects in this study were in the age group of 55–59 years. This finding is consistent with some previous studies which stated that the majority of lung adenocarcinoma patients receiving EGFR-TKI treatment were more than 45 years old with an average of 61.8-year old [10]. Another study also found that adenocarcinoma patients mostly fell in the age group of 40–49 years [11]. The largest epidemiological study of adenocarcinoma patients in Asia, the PIONEER study, reported that the average age of adenocarcinoma patients in Asia was 60 years old, ranged from 17 to 94 years old [12].

In this study, most subjects were male patients, consistent with the results of a study conducted by The International Agency for Research on Cancer (IARC). IARC reported a high incidence of lung cancer cases in male, particularly in Asia, North America, Middle East, and South Europe, with

the incident rate ranging from 48.5 to 56.5 per 100,000 cases [13]. Another study also found that lung adenocarcinoma cancer was mostly (63%) found in males [11]. The ratio of lung adenocarcinoma cancer cases between males and females was 7.4:1 [14].

Smoking is one obvious risk factor for lung cancer. Some research reported that secondhand smoke decreases the function of ciliary follicles. The lung's physiological ability to expel foreign material would decrease, and it leads to adenocarcinoma in long-term period [15, 16]. In this study, most of our subjects were nonsmokers (51.6%). Our result was in accord with a study which also reported that the majority of female lung adenocarcinoma patients (86.6%) were nonsmokers [17].

In our study, most of the samples for histopathological diagnosis of adenocarcinoma were taken from lung mass (86.8%). Most of them (59.7%) were obtained via fine-needle aspiration biopsy (FNAB) technique. As had been reported in IGNITE study, FNAB was used as sampling technique as much as 51% in Indonesia compared to 40.4% in Thailand [8, 10]. Most subjects in our study were in advanced stage of disease (stage IVA 66.9% and stage IVB 11.3%). Elhidsi et al. [10] also reported that most of their patients were diagnosed with stage IV lung adenocarcinoma when they were first brought to health services (44.6% stage IVA and 43.1% stage IVB). Our findings were also consistent with a previous study conducted in India, stating that lung adenocarcinoma patients presented mostly (82%) in stage IV disease at diagnosis [14].

The positive plasma EGFR mutation detected in ctDNA in our study was 27.4%. Other study, the PIONEER study, reported a proportion of positive EGFR mutation of lung adenocarcinoma in seven Asian countries ranging from 22 to 64% [12]. Similar results were also found in a study conducted by Oktaviyanti in Indonesia, which reported that 34% of

Table 2 Association between subject characteristics and EGFR mutation status of ctDNA sample

Characteristics	β	p	OR	CI for OR
Age ≤ 65 vs > 65	0.220	0.042	1.246	0.415–2.316
Female vs male	–0.030	0.961	0.970	0.407–4.571
Nonsmoker vs smoker	1.740	< 0.001	5.698	1.283–5.590

Dependent, EGFR ctDNA

Table 3 Disease stage and the positivity of EGFR mutation detection in ctDNA sample

CA	Positive EGFR mutation (%) <i>n</i> = 34	Wild type (%) <i>n</i> = 90	Total (%) <i>n</i> = 124
IIA	0 (0.00)	2 (100.00)	2 (1.61)
IIB	0 (0.00)	3 (100.00)	3 (2.42)
IIIA	0 (0.00)	11 (100.00)	11 (8.87)
IIIB	0 (0.00)	5 (100.00)	5 (4.03)
IIIC	1 (16.60)	5 (83.33)	6 (4.84)
IVA	25 (30.12)	58 (69.88)	83 (66.93)
IVB	8 (57.14)	6 (42.86)	14 (11.29)

adenocarcinoma patients had positive EGFR mutation [11]. The type of EGFR mutations in our study was dominated by common EGFR mutation (97%), consisted of 72.7% mutations in exon 19 and 27.2% mutations in exon 21. Our finding was also consistent with results of study conducted by Pirker et al. [18] and the IGNITE study [8]. Pirker et al. found that EGFR common mutation was around 85–90%, consisted of exon 19 deletion mutations (45%) and L858R exon 21 mutations (40–45%) [18]. Likewise, the IGNITE study on populations in the Asia-Pacific region found EGFR common mutations of 91.2%, consisted of exon 19 deletion mutations (48.7%) and L858R exon 21 mutations (42.5%) [8]. Most of the metastasis in our study was in the pleura (52.4%) which is also consistent with the result of Elhidsi et al., where pleural metastases was the highest frequency of metastatic lesion in lung adenocarcinoma patients at 66.1% [10].

The ctDNA detection of EGFR mutation is more likely positive in more advanced stage lung cancer. In other words, subjects with advanced disease stages had the highest probability of EGFR mutations detected in ctDNA and would be lowest in the early stages. In our study, positive EGFR mutations were detected strongly in stage IVB (57.1%) and stage IVA (30.1%) and were not detected at all in stage I–IIIB. These findings were similar to those reported by Elhidsi et al., who found that most of EGFR mutations in lung adenocarcinoma were detected in advanced stages, i.e., stage IIIB–IV [10]. Plasma samples of patients with lung cancer contained very high DNA when compared to non-cancer patients and would increase especially in the advanced cancer stage. Most circulatory DNA release is believed to originate from cancer cells that die in the primary place or tumor metastasis [19]. Therefore, plasma DNA has proven to be a non-invasive source of genotypic information that can be used to replace tumor tissue in detecting tumor-specific molecular

markers. It can also be used to access the therapeutic response and patients' prognosis [20–22].

The association between tumor stage and the success rate of ctDNA detection has evolved through various recent studies. Those studies reported that ctDNA could be detected in 82–100% of stage IV patients, while only 47% of ctDNA was detected in patients with stage I lung tumors [23]. In our study, only age and smoking status variables had a significant correlation with positive EGFR detections from ctDNA testing. The significance value of nonsmokers was $p < 0.001$, odd ratio = 5.698, and R square = 15.2%. These results indicated a relationship of nonsmoking status with lung adenocarcinoma EGFR mutation case, but the effect was only 15.2%, with the assumption that the EGFR mutation positivity will increase by 5.698 times greater in nonsmoker patients compared to smoker patients. These findings were consistent with a study conducted by Shigematsu et al., who found that NSCLC patients had more gene mutations in nonsmoker patients (51%), compared to smokers (10%) [24]. Thus, there is no correlation between the occurrence of EGFR mutation and the act of smoking. Patients with positive EGFR mutation will easily develop lung cancer, including the nonsmoker group. This proves that genetic inheritance is more influential than the environment, as also reported by Tsao et al. [25].

The significance value of age was $p = 0.042$, odd ratio = 1.246, and R square was 15.2%. These findings indicated that the age of 65 years could increase EGFR mutation by 1.246 times greater compared to age group less than 65 years, but the effect was only 15.2%. The tendency of the data showed that the older the age, the higher the risk for cancer. A study conducted in 2014 reported that the tendency of smoking patterns according to age also influenced the occurrence of lung cancer. The age group of 50–64 years had the highest gene inactivation in the CDH1 and GSTP1 genes, while the age group

Table 4 Concordance of EGFR mutation status between cytological specimens and ctDNA (plasma)

	Concordance rate		Sensitivity		Specificity		PPV		NPV	
	<i>n</i> (%)	CI 95%	<i>n</i> (%)	CI 95%	<i>n</i> (%)	CI 95%	<i>n</i> (%)	CI 95%	<i>n</i> (%)	CI 95%
EGFR ctDNA	88/124 (70.97)	62–79	28/58 (48.3)	35–62	60/66 (90.9)	81–97	28/34 (82.35)	68–91	60/90 (66.67)	61–72

of > 70 years had the highest tendency to inactivate the GTSP1 and RASSF1A genes among other age groups. This indicates that the age group above 65 years has a higher risk of developing lung cancer compared to the population less than 65 years of age [26]. A study on cancer incidence in Korea also showed a tendency that lung cancer occurred in men and women over 65 years [27].

In our study, compared to detection in cytological specimens, the EGFR mutation detection in ctDNA had a sensitivity of 48.3%, with a specificity of 90.9%, PPV of 82.35%, NPV of 66.7%, and 70.97% concordance rate. This finding was also consistent with the IGNITE study that showed a concordance rate of 77.7% [8]. Some previous clinical trials argued that ctDNA detection is an appropriate alternative method for the determination of EGFR mutation status [28–30]. In real-life condition, the ASSESS study reported the use of plasma ctDNA derivatives, and their concordance values were quite good according to the results of tissue/cytology samples which is of 89% (with sensitivity of 46%, specificity of 97%, PPV of 78%, and NPV of 90%) [31]. Some other recent studies, including two meta-analyses of the concordance of EGFR mutation between plasma and tissue, showed a high concordance rate even though with somewhat low sensitivity value of 62–67% [32, 33].

Conclusion

Lung adenocarcinoma patients who underwent EGFR examination at Dr. Soetomo General Hospital, Surabaya, Indonesia, were mostly male, in the age range of 55–59 years, and non-smokers. FNAB was the most common sampling technique for cytological specimens testing. Most of the specimens were taken from lung mass. Most of the patients had stage IVA disease with pleural metastases. The EGFR mutation was detected in 47.6% of patients from cytological specimens and in 27.4% of patients from ctDNA. The majority of EGFR mutations were in exon 19 and exon 21. EGFR mutation was increasingly detected as the disease stage increased, with the strongest detection in stage IVB (57.1%). The EGFR mutation detection in ctDNA had a high concordance rate with cytological specimens' examination and thus had the potential to be used as an alternative method to determine the EGFR mutation in adenocarcinoma NSCLC patients in whom an adequate tissue sample cannot be obtained.

Acknowledgements We would like to thank Astra Zeneca Indonesia Ltd. for the support of ctDNA testing.

Compliance with Ethical Standards

Conflict of Interest The authors declare that they have no conflict of interest.

References

1. Fatmawati F (2016) Profil Pasien Kanker Paru Jenis Karsinoma Bukan Sel Kecil yang Mendapatkan Inhibitor Tirosin Kinase Sebagai Terapi Lini Pertama di RSUD Dr. Universitas Airlangga, Soetomo
2. Hudoyo A, Wibawanto A, Lutfi A, Rima A, Putra AC, Ratnawati A, Febriani A, Jusuf A, Harsal A, Westi A, Icksan AG, Heru B, Tobing DL, Soeis DS, Paramita D, Syahrudin E, tenda ED, Diana ES, Suzanna E, Dewi FL, Djuita F, Prajogi GB, Iskandar H, Hidayat H, Indriani PI, Zaini J, Juniarti KJ, Kardinah RKW, KBH P, Wulandari L, Lisnawati M, Supriana N, Lubis N, Soeroso NNG, Soetandoyo N, Nuhonni SA, Siregar N, Dilangga P, Prasenhadi AP, Pahlesia R, Sembiring RE, Ermayanti S, Anggoro SC, Tarigan SP, Andarini SL, Gondhowiardjo S, Munir SM, Pratiwi SD, Seto RS, Mety SH, Endardjo S, Aniwidyaningsih W, Soeharno W, Amin Z (2017) Pedoman Nasional Pelayanan Kedokteran Kanker Paru. Kementerian Kesehatan Republik Indonesia, Jakarta
3. Jusuf A, Harryanto A, Syahrudin E, Endardjo S, Mudjiantoro S, Sutandio N (2005) Kanker paru jenis karsinoma bukan sel kecil. Pedoman nasional untuk diagnosis dan penatalaksanaan di Indonesia
4. VandenBussche CJ, Illei PB, Lin M-T, Ettinger DS, Maleki Z (2014) Molecular alterations in non-small cell lung carcinomas of the young. *Hum Pathol* 45(12):2379–2387. <https://doi.org/10.1016/j.humpath.2014.08.005>
5. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B (2010) EGFR-mutated lung cancer: a paradigm of molecular oncology. *Oncotarget* 1(7):497–514. <https://doi.org/10.18632/oncotarget.186>
6. Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB (2015) Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK, and ROS1 genomic alterations via comprehensive genomic profiling. *Clin Lung Cancer* 16(5):e105–e109. <https://doi.org/10.1016/j.clcc.2015.03.002>
7. Oh JE, An CH, Yoo NJ, Lee SH (2011) Detection of low-level EGFR T790M mutation in lung cancer tissues. *APMIS* 119(7):403–411. <https://doi.org/10.1111/j.1600-0463.2011.02738.x>
8. Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Laktionov K, Hudoyo A, He Y, Zhang Y-P, Wang M-Z, Liu CY, Ratcliffe M, McCormack R, Reck M (2017) EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study. *Lung Cancer* 113:37–44. <https://doi.org/10.1016/j.lungcan.2017.08.021>
9. Zhu G, Ye X, Dong Z, Lu YC, Sun Y, Liu Y, McCormack R, Gu Y, Liu X (2015) Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. *J Mol Diagn* 17(3):265–272. <https://doi.org/10.1016/j.jmoldx.2015.01.004>
10. Elhidsi M, Andarini SL, Hudoyo A (2016) Profil Mutasi epidermal growth factor receptor Pasien Adenokarsinoma Paru Usia Muda. *Jurnal Respirologi Indonesia* 4(36):244–247
11. Oktaviyanti IK (2015) Mutasi Egfr Pada Pemeriksaan Sitologi Adenokarsinoma Paru. *Berkala Kedokteran Unlam* 11(2):213–219
12. Shi Y, Au JS-K, Thongprasert S, Srinivasan S, Tsai C-M, Khoa MT, Heeroma K, Itoh Y, Comelio G, Yang P-C (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). *J Thorac Oncol* 9(2):154–162. <https://doi.org/10.1097/JTO.0000000000000033>

13. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 136(5):E359–E386. <https://doi.org/10.1002/ijc.29210>
14. Mohan A, Latifi A, Guleria R (2016) Increasing incidence of adenocarcinoma lung in India: following the global trend? *Indian J Cancer* 53(1):92–92, 95
15. Chen J, Qi Y, Wampfler JA, Jatoi A, Garces YI, Busta AJ, Mandrekar SJ, Yang P (2012) Effect of cigarette smoking on quality of life in small cell lung cancer patients. *Eur J Cancer (Oxford, England : 1990)* 48(11):1593–1601. <https://doi.org/10.1016/j.ejca.2011.12.002>
16. Rezaei S, Karami Matin B, Kazemi Karyani A, Woldemichael A, Khosravi F, Khosravipour M, Rezaeian S (2017) Impact of smoking on health-related quality of life: a general population survey in West Iran. *Asian Pac J Cancer Prev* 18(11):3179–3185. <https://doi.org/10.22034/APJCP.2017.18.11.3179>
17. Prudkin L, Tang X, Wistuba II (2009) Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. *J Thorac Oncol* 4(1):139–141. <https://doi.org/10.1097/JTO.0b013e3181915f92>
18. Pirker R, Herth FJF, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R (2010) Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. *J Thorac Oncol* 5(10):1706–1713. <https://doi.org/10.1097/JTO.0b013e3181f1c8de>
19. Sozzi G, Conte D, Leon M, Cirincione R, Roz L, Ratcliffe C, Roz E, Cirenei N, Bellomi M, Pelosi G, Pierotti MA, Pastorino U (2003) Quantification of free circulating DNA as a diagnostic marker in lung Cancer. *J Clin Oncol* 21(21):3902–3908. <https://doi.org/10.1200/jco.2003.02.006>
20. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J (2009) Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung Cancer. *J Clin Oncol* 27(16):2653–2659. <https://doi.org/10.1200/jco.2008.17.3930>
21. Yung TKF, Chan KCA, Mok TSK, Tong J, To K-F, Lo YMD (2009) Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung Cancer patients. *Clin Cancer Res* 15(6):2076–2084. <https://doi.org/10.1158/1078-0432.ccr-08-2622>
22. Jian G, Songwen Z, Ling Z, Qinfang D, Jie Z, Liang T, Caicun Z (2010) Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. *J Cancer Res Clin Oncol* 136(9):1341–1347. <https://doi.org/10.1007/s00432-010-0785-z>
23. Bettgowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Lubner B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong S-M, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SKN, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih L-M, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang T-L, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med* 6(224):224ra224–224ra224. <https://doi.org/10.1126/scitranslmed.3007094>
24. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 97(5):339–346
25. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I (2006) Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung Cancer. *J Thorac Oncol* 1(3):231–239. [https://doi.org/10.1016/S1556-0864\(15\)31573-2](https://doi.org/10.1016/S1556-0864(15)31573-2)
26. Vaissière T, Sawan C, Hecceg Z (2008) Epigenetic interplay between histone modifications and DNA methylation in gene silencing. *Mutation Research/Reviews in Mutation Research* 659(1):40–48. <https://doi.org/10.1016/j.mrrev.2008.02.004>
27. Jung K-W, Won Y-J, Kong H-J, Oh C-M, Lee DH, Lee JS (2014) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. *Cancer Res Treat* 46(2):109–123. <https://doi.org/10.4143/crt.2014.46.2.109>
28. Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T, McCormack R (2014) Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. *J Thorac Oncol* 9(9):1345–1353. <https://doi.org/10.1097/JTO.0000000000000263>
29. Mok T, Wu Y-L, Lee JS, Yu C-J, Sriuranpong V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao M, Zhu Y, Zhou C, Fuerte F, Margono B, Wen W, Tsai J, Truman M, Klughammer B, Shames DS, Wu L (2015) Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. *Clin Cancer Res* 21(14):3196–3203. <https://doi.org/10.1158/1078-0432.ccr-14-2594>
30. Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez JM, Porta R (2015) Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. *JAMA Oncol* 1(2):149–157
31. Reck M, Hagiwara K, Han B, Tjulandin S, Grohé C, Yokoi T, Morabito A, Novello S, Arriola E, Molinier O, McCormack R, Ratcliffe M, Normanno N (2016) ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study. *J Thorac Oncol* 11(10):1682–1689. <https://doi.org/10.1016/j.jtho.2016.05.036>
32. Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F, Xu L, Yin R (2015) Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. *Cancer epidemiology biomarkers & prevention* 24(1):206–212. <https://doi.org/10.1158/1055-9965.epi-14-0895>
33. Luo J, Shen L, Zheng D (2014) Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. *Sci Rep* 4:6269–6269. <https://doi.org/10.1038/srep06269>



**KOMITE ETIK PENELITIAN KESEHATAN
RSUD Dr. SOETOMO SURABAYA**

**KETERANGAN KELAIKAN ETIK
(" ETHICAL CLEARANCE ")**

0209/KEPK/IV/2018

**KOMITE ETIK RSUD Dr. SOETOMO SURABAYA TELAH MEMPELAJARI
SECARA SEKSAMA RANCANGAN PENELITIAN YANG DIUSULKAN, MAKA
DENGAN INI MENYATAKAN BAHWA PENELITIAN DENGAN JUDUL :**

**" PROPOSAL PENELITIAN PERBANDINGAN DETEKSIMUTASI
GENEPIDERMAL GROWTHFACTOR RECEPTOR(EGFR)PADA PLASMA
DARAHEPI (LIQUID BIOPSY) DENGAN HISTOPATOLOGI ANATOMI PADA
PASIENADENOKARSINOMA PARU "**

PENELITI UTAMA : Laksmi Wulandari, dr.,Sp.P(K), FCCP

**PENELITI LAIN : 1. Anna Febriani, dr., Sp.P
2. Farah Fatmawati, dr., S.P
3. Sahrin, dr.**

UNIT / LEMBAGA / TEMPAT PENELITIAN : RSUD Dr. Soetomo

DINYATAKAN LAIK ETIK

Berlaku dari : 19/04/2018 s.d 19/04/2019

Surabaya, 19 April 2018

KETUA

(Dr. Elizeus Hanindito, dr., Sp.An, KIC,KAP)

NIP. 19511007 197903 1 002

****) Sertifikat ini dinyatakan sah apabila telah mendapatkan stempel asli dari Komite Etik***



Source details

Indian Journal of Surgical Oncology

Scopus coverage years: from 2010 to Present

Publisher: Springer Nature

ISSN: 0975-7651 E-ISSN: 0976-6952

Subject area: Medicine: Surgery Medicine: Oncology

Source type: Journal

CiteScore 2020

0.7



SJR 2020

0.231



SNIP 2020

0.420



[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

i Improved CiteScore methodology



CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. [Learn more >](#)

CiteScore 2020

$$0.7 = \frac{386 \text{ Citations 2017 - 2020}}{570 \text{ Documents 2017 - 2020}}$$

Calculated on 05 May, 2021

CiteScoreTracker 2021

$$0.9 = \frac{570 \text{ Citations to date}}{630 \text{ Documents to date}}$$

Last updated on 06 March, 2022 • Updated monthly

CiteScore rank 2020

Category	Rank	Percentile
Medicine Surgery	#311/422	26th
Medicine Oncology	#276/340	18th

[View CiteScore methodology >](#) [CiteScore FAQ >](#) [Add CiteScore to your site](#)



←

Ads by Google

Stop seeing this ad Why this ad? ⓘ

F1000Research

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
<p>United Kingdom</p>	<p>Biochemistry, Genetics and Molecular Biology</p> <ul style="list-style-type: none"> Biochemistry, Genetics and Molecular Biology (miscellaneous) <p>Immunology and Microbiology</p> <ul style="list-style-type: none"> Immunology and Microbiology (miscellaneous) <p>Medicine</p> <ul style="list-style-type: none"> Medicine (miscellaneous) <p>Pharmacology, Toxicology and Pharmaceutics</p> <ul style="list-style-type: none"> Pharmacology, Toxicology and Pharmaceutics (miscellaneous) 		<p>60</p>
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	20461402	2012-2020	<p>Homepage</p> <p>How to publish in this journal</p> <p>research@f1000.com</p>

SCOPE

F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.

Join the conversation about this journal

Quartiles


↓

←

Ads by Google

Stop seeing this ad Why this ad? ⓘ

<p>Advances in Experimental Medicine and Biology USA</p> <p>79% similarity</p>	<p>EBioMedicine NLD</p> <p>78% similarity</p>	<p>Science Translational Medicine USA</p> <p>73% similarity</p>	<p>Frontiers of Medicine CHN</p> <p>73% similarity</p>	<p>Journal of Biomedical Science GBR</p> <p>71% similarity</p>
--	---	---	--	--



Metrics based on Scopus® data as of April 2021

H hany akeel naji 8 months ago
I have been waiting about one year for my article to publish or review but till now nothing happened
← reply

Melanie Ortiz 8 months ago SCImago Team
Dear Hany,
Thank you for contacting us.
Unfortunately, we cannot help you with your request, we suggest you contact the journal's editorial staff, so they could inform you more deeply.
Best Regards, SCImago Team

A alemu 12 months ago
Background: Nowadays, people die due to metabolic aging than chronological age worldwide.

Ads by Google

Stop seeing this ad Why this ad? ⓘ